X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9893) 9893
Dissertation (37) 37
Book Chapter (36) 36
Publication (17) 17
Magazine Article (8) 8
Conference Proceeding (7) 7
Web Resource (6) 6
Book Review (2) 2
Reference (2) 2
Book / eBook (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cetuximab (8070) 8070
humans (7068) 7068
oncology (5356) 5356
female (3175) 3175
male (2976) 2976
chemotherapy (2968) 2968
cancer (2765) 2765
middle aged (2553) 2553
colorectal cancer (2393) 2393
aged (2342) 2342
antibodies, monoclonal, humanized (2230) 2230
colorectal neoplasms - drug therapy (1979) 1979
antineoplastic agents - therapeutic use (1833) 1833
adult (1816) 1816
antineoplastic combined chemotherapy protocols - therapeutic use (1771) 1771
antibodies, monoclonal - therapeutic use (1631) 1631
growth-factor receptor (1624) 1624
mutation (1447) 1447
egfr (1443) 1443
receptor, epidermal growth factor - antagonists & inhibitors (1427) 1427
colorectal neoplasms - pathology (1425) 1425
treatment outcome (1404) 1404
bevacizumab (1354) 1354
metastasis (1315) 1315
animals (1245) 1245
colorectal neoplasms - genetics (1235) 1235
care and treatment (1234) 1234
1st-line treatment (1146) 1146
therapy (1132) 1132
panitumumab (1091) 1091
aged, 80 and over (1090) 1090
cell line, tumor (1084) 1084
epidermal growth factor (1078) 1078
survival (1047) 1047
tumors (1039) 1039
prognosis (1023) 1023
fluorouracil (1001) 1001
expression (971) 971
antibodies, monoclonal - administration & dosage (962) 962
oxaliplatin (948) 948
radiotherapy (929) 929
squamous-cell carcinoma (895) 895
kras (878) 878
research (848) 848
disease-free survival (840) 840
receptor, epidermal growth factor - metabolism (835) 835
analysis (814) 814
ras proteins - genetics (802) 802
monoclonal antibodies (799) 799
mice (781) 781
neoplasm metastasis (766) 766
hematology, oncology and palliative medicine (745) 745
head and neck neoplasms - drug therapy (744) 744
antineoplastic agents - pharmacology (738) 738
carcinoma, squamous cell - drug therapy (736) 736
irinotecan (732) 732
squamous cell carcinoma (729) 729
cisplatin (722) 722
head and neck cancer (722) 722
proto-oncogene proteins p21 (712) 712
pharmacology & pharmacy (703) 703
proto-oncogene proteins - genetics (703) 703
camptothecin - analogs & derivatives (692) 692
leucovorin (682) 682
antineoplastic agents (680) 680
plus cetuximab (680) 680
epidermal growth factor receptor (675) 675
metastatic colorectal-cancer (673) 673
cancer therapies (671) 671
antibodies, monoclonal - adverse effects (670) 670
trial (663) 663
medicine & public health (659) 659
surgery (657) 657
antineoplastic agents - adverse effects (636) 636
retrospective studies (630) 630
carcinoma (626) 626
combination (624) 624
antimitotic agents (617) 617
open-label (616) 616
drug therapy (615) 615
fluorouracil - administration & dosage (615) 615
neoplasm staging (606) 606
patients (600) 600
colorectal-cancer (584) 584
antibodies, monoclonal - pharmacology (582) 582
phase-ii (582) 582
health aspects (581) 581
neoplasms (578) 578
head (570) 570
genetic aspects (568) 568
gefitinib (558) 558
antineoplastic combined chemotherapy protocols - adverse effects (552) 552
phase-iii trial (548) 548
receptor, epidermal growth factor - genetics (546) 546
digestive system diseases (538) 538
monoclonal-antibody (517) 517
cetuximab - administration & dosage (513) 513
cetuximab plus irinotecan (511) 511
cell lung-cancer (510) 510
camptothecin - administration & dosage (504) 504
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9310) 9310
French (227) 227
German (174) 174
Japanese (166) 166
Spanish (61) 61
Chinese (58) 58
Czech (29) 29
Korean (19) 19
Hungarian (14) 14
Russian (13) 13
Italian (11) 11
Dutch (6) 6
Polish (6) 6
Turkish (6) 6
Portuguese (5) 5
Norwegian (3) 3
Finnish (2) 2
Hebrew (2) 2
Arabic (1) 1
Catalan (1) 1
Danish (1) 1
Icelandic (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 2015, Volume 6, Issue 28, pp. 24780 - 24796
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 1000 - 8
Backgrounds Overexpression of epidermal growth factor receptor (EGFR) has been established as a valid therapeutic target of non-small cell lung cancer (NSCLC).... 
CHEMOTHERAPY PLUS CETUXIMAB | RADIOIMMUNOTHERAPY | ANTIBODY | BIODISTRIBUTION | Immuno-PET | Personalized medicine | EGFR | GROWTH-FACTOR RECEPTOR | ONCOLOGY | Non-small cell lung cancer | EGFR EXPRESSION | MICE | CU-64-DOTA-CETUXIMAB | Cetuximab | BINDING | Cu-64 | Lung Neoplasms - drug therapy | Cetuximab - chemistry | Humans | Lung Neoplasms - metabolism | Cetuximab - metabolism | Lung Neoplasms - pathology | Cetuximab - therapeutic use | Antineoplastic Agents, Immunological - chemistry | Tissue Distribution | Radiopharmaceuticals - metabolism | Heterocyclic Compounds, 1-Ring - chemistry | Female | Copper Radioisotopes - chemistry | Carcinoma, Non-Small-Cell Lung - pathology | ErbB Receptors - metabolism | Radiopharmaceuticals - chemistry | Carcinoma, Non-Small-Cell Lung - metabolism | Positron-Emission Tomography - methods | Heterocyclic Compounds, 1-Ring - metabolism | Antineoplastic Agents, Immunological - metabolism | Xenograft Model Antitumor Assays | Animals | Antineoplastic Agents, Immunological - therapeutic use | Mice, Nude | Cell Line, Tumor | Lung Neoplasms - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Mice | Mice, Inbred BALB C | Carcinoma, Non-Small-Cell Lung - drug therapy | Copper Radioisotopes - metabolism | Usage | Care and treatment | PET imaging | Genetic aspects | Research | Lung cancer, Non-small cell | Gene expression | 64Cu
Journal Article
Journal Article
Clinical cancer research, ISSN 1557-3265, 2015, Volume 21, Issue 16, pp. 3658 - 3666
Journal Article
International journal of cancer, ISSN 1097-0215, 2019, Volume 145, Issue 9, pp. 2450 - 2458
Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off is approved in colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma.... 
cetuximab | metastatic colorectal cancer | phase 1 | regorafenib | HEAD | MULTICENTER | PLUS CETUXIMAB | ANGIOGENESIS | CHEMOTHERAPY | ONCOLOGY | COLORECTAL-CANCER | GROWTH | DOUBLE-BLIND | CARCINOMA | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Phenylurea Compounds - therapeutic use | Pyridines - pharmacokinetics | Male | Treatment Outcome | Cetuximab - therapeutic use | Cetuximab - pharmacokinetics | Cetuximab - adverse effects | Neoplasms - drug therapy | Young Adult | Maximum Tolerated Dose | Pyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Phenylurea Compounds - adverse effects | Drug Interactions - physiology | Adult | Female | Aged | Phenylurea Compounds - pharmacokinetics | Pyridines - therapeutic use | Complications and side effects | Medical research | Care and treatment | Safety and security measures | Colorectal cancer | Medicine, Experimental | Metastasis | Cancer | Intravenous administration | Toxicity | Colorectal carcinoma | Diarrhea | Hepatocellular carcinoma | Pharmacology | Dermatitis | Metastases | Hypophosphatemia | Skin | Safety | Solid tumors | Pharmacokinetics | Drug dosages | Arm | Tumors | Index Medicus | Cancer Therapy and Prevention
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
The Lancet (British edition), ISSN 0140-6736, 01/2019, Volume 393, Issue 10166, pp. 51 - 60
The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal... 
yes | DYSPHAGIA | HEAD | MEDICINE, GENERAL & INTERNAL | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | P16 STATUS | ASSOCIATION | EXPRESSION | NECK-CANCER | Oropharyngeal Neoplasms - therapy | Chemoradiotherapy - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Male | Antineoplastic Agents - therapeutic use | Oropharyngeal Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Cetuximab - therapeutic use | Radiotherapy, Intensity-Modulated - adverse effects | Squamous Cell Carcinoma of Head and Neck - virology | Cetuximab - adverse effects | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Female | Acute Disease | Chemoradiotherapy - methods | Papillomavirus Infections - complications | Drug Administration Schedule | Risk Assessment | Radiotherapy, Intensity-Modulated - methods | Kaplan-Meier Estimate | Treatment Outcome | Oropharyngeal Neoplasms - virology | Cisplatin - therapeutic use | Cisplatin - adverse effects | Cetuximab - administration & dosage | Squamous Cell Carcinoma of Head and Neck - therapy | Neoplasm Staging | Papillomaviruses | Radiotherapy | Throat cancer | Papillomavirus infections | Head | Intravenous administration | Toxicity | Health risks | Risk | Radiation therapy | FDA approval | Cancer therapies | Patients | Evidence-based medicine | Cisplatin | Quality of life | Human papillomavirus | Randomization | Epidermal growth factor | Motivation | Oropharyngeal cancer | Head and neck | Head & neck cancer | Growth factors | Smoking | Cancer | Tumors
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 1, pp. 110 - 117
Purpose To assess the rate of serious (>Grade 2, CTCAE 3.0) dermatitis in our head-and-neck cancer (HNC) patients undergoing simultaneous integrated boost... 
Radiology | Hematology, Oncology and Palliative Medicine | Cetuximab and IMRT | Cetuximab-related dermatitis | Cetuximab in irradiated head neck cancer | Cetuximab and bolus material | RADIOTHERAPY PLUS CETUXIMAB | RASH | ONCOLOGY-GROUP | PHASE-III | SECONDARY | RANDOMIZED-TRIAL | COMBINATION | RADIATION-THERAPY | CISPLATIN | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Prospective Studies | Drug Eruptions - pathology | Humans | Middle Aged | Radiodermatitis - chemically induced | Antibodies, Monoclonal - adverse effects | Male | Antineoplastic Agents - administration & dosage | Case-Control Studies | Radiotherapy, Intensity-Modulated - adverse effects | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Cetuximab | Radiodermatitis - pathology | Drug Eruptions - etiology | Radiotherapy, Intensity-Modulated - methods | Radiation Dosage | Tumor Burden | Combined Modality Therapy - adverse effects | Head and Neck Neoplasms - pathology | Head and Neck Neoplasms - radiotherapy | Antibodies, Monoclonal - administration & dosage | Aged | Combined Modality Therapy - methods | HEAD | NEOPLASMS | DERMATITIS | RADIATION DOSES | SKIN DISEASES | MEDICINE | NUCLEAR MEDICINE | ORGANS | NECROSIS | DISEASES | THERAPY | DOSES | RADIOLOGY AND NUCLEAR MEDICINE | NECK | RADIOTHERAPY | SKIN | BODY | PATHOLOGICAL CHANGES | RADIOLOGY
Journal Article
Nature (London), ISSN 1476-4687, 2015, Volume 526, Issue 7572, pp. 263 - 267
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly... 
PANITUMUMAB | THERAPY | MULTIDISCIPLINARY SCIENCES | SEQUENCE | ACQUIRED-RESISTANCE | SOMATIC MUTATION | IDENTIFICATION | GENE COPY NUMBER | ACTIVATING MUTATIONS | BREAST | INSIGHTS | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | MAP Kinase Kinase 1 - genetics | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Insulin Receptor Substrate Proteins - genetics | Colorectal Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Cetuximab - pharmacology | DNA Copy Number Variations - genetics | Mutation - genetics | Genome, Human - genetics | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Exome - genetics | Animals | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Colorectal cancer | Drug metabolism | Genetic aspects | Identification and classification | Health aspects | Proteins | Epidermal growth factor | Genes | Clinical trials | Mutation | Kinases | Cancer therapies | Tumors
Journal Article
Journal Article
Journal Article